Your SlideShare is downloading. ×
0
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Multiple sclerosis
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Multiple sclerosis

12,978

Published on

Dr Kupe's Note on Multiple Sclerosis

Dr Kupe's Note on Multiple Sclerosis

Published in: Health & Medicine
2 Comments
31 Likes
Statistics
Notes
No Downloads
Views
Total Views
12,978
On Slideshare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
1,085
Comments
2
Likes
31
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. DRKUPE’S NOTE ON drkupe MULTIPLE SCLEROSIS Irfan Ziad MD UCD
  • 2. is an inflammatory disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms M U L T I P L E SCLEROSIS
  • 3. > Predominant age: 20-40 MULTIPLE SCLEROSIS AFFECT: 0.1% Worldwide incidence Higher incidence in Northern European descent and in temperate climate, but the latitude gradient is decreasing The ratio is increasing now people in US have MS 400, 000 1–3% risk of MS among 1st-degree relatives worse prognosis Highly variable and unpredictable
  • 4. Pathophysiology Blood-brain barrier breakdown The BBB prevent entrance of T cells into the nervous system. The blood–brain barrier is normally not permeable to these types of cells, unless triggered by infection or a virus, which decreases the integrity of the tight junctions. When the blood–brain barrier regains its integrity, usually after infection or virus has cleared, the T cells are trapped inside the brain. Autoimmunology The immune system attacks the nervous system, forming plaques or lesions. Commonly involves white matter. Destroys oligodendrocytes- causing demyelination Remyelination occurs in early phase but not completely. Repeated attacks lead to fewer remyelination. Inflammation T-cells attacks on myelin triggers inflammatory processes, stimulating other immune cells and soluble factors like cytokines and antibodies. Leaks form in the BBB cause swelling, activation of macrophages, and more activation of cytokines and other destructive proteins
  • 5. PRMS Progressive Relapsing MS SPMS Secondary Progressive MS PPMS Primary Progressive MS RRMS Relapsing/ Remitting MS CLASSIFICATION OF MULTIPLE SCLEROSIS Gradual progression of the disease from its onset with no relapses or remissions Unpredictable attacks which may or may not leave permanent deficits followed by periods of remission Initial RRMS that suddenly begins to decline without periods of remission and relapses. Steady decline since onset with super-imposed attacks.
  • 6. <ul><li>The most common initial symptoms </li></ul><ul><li>changes in sensation in the arms, legs or face (33%) </li></ul><ul><li>Optic neuritis (20%) </li></ul><ul><li>weakness (13%) </li></ul><ul><li>double vision- internuclear opthalmoplegia (7%) </li></ul><ul><li>unsteadiness when walking (5%) </li></ul><ul><li>and balance problems (3%) </li></ul>Lhermitte&apos;s sign  (25-40%) is an electrical sensation that runs down the back and into the limbs and is produced by bending the neck forwards. The sign suggests a lesion of the dorsal columns of the cervical cord or of the caudal medulla. Uhthoff&apos;s phenomenon is the worsening of neurologic symptoms in multiple sclerosis and other neurological, demyelinating conditions when the body gets overheated from hot weather, exercise, fever, or saunas and hot tubs.
  • 7. EDSS is a method of quantifying disability in multiple sclerosis based on eight Functional Systems (FS) Expanded Disability Status Scale (EDSS) <ul><li>Pyramidal (ability to walk) </li></ul><ul><li>Cerebellar (coordination) </li></ul><ul><li>Brain stem (speech and swallowing) </li></ul><ul><li>Sensory (touch and pain) </li></ul><ul><li>Bowel and bladder functions </li></ul><ul><li>Visual </li></ul><ul><li>Mental </li></ul><ul><li>Other (any other neurological findings) </li></ul>Normal Neurological Exam 0.0 Death due to MS 10.0 1.0 4.5 5.0 9.5 Fully ambulatory Ambulation impairment A graph showing the average time a person spends in each EDSS level.
  • 8. Diagnosis is based on McDonald’s Criteria (Revised 2010) INVESTIGATION CSF oligoclonal bands, abnormal colloidal gold curve, elevated γ- globulin IgG, mild mononuclear pleocytosis (&lt;40 cells/mL), myelin debris, normal or slightly elevated protein. (Myelin basic Protein) Blood test <ul><li>B-12 and folate levels or antinuclear antibody (ANA) titers. </li></ul><ul><li>Antiphospholipid antibody syndrome must be undertaken in patients with evidence of blood dyscrasia and in women with unexplained miscarriages or history of deep venous thrombosis. </li></ul><ul><li>elevated erythrocyte sedimentation rate (ESR) and positive titers of rheumatoid factor (RF) should help identify the presence of a vasculitic disorder that may be mimicking MS. </li></ul>MRI MRI of the head and spine (more sensitive than CT): May show many plaques. MRI reveals multiple lesions with high T2 signal intensity and one large white matter lesion. These demyelinating lesions may sometimes mimic brain tumors because of the associated edema and inflammation.
  • 9. &amp;quot;Dawson&apos;s Fingers” is the name for the multiple sclerosis lesions around the ventricle-based brain veins of Multiple Sclerosis patients seen on MRI
  • 10. MANAGEMENT Steroids: methylprednisolone (MP) 500–1,000 mg/d IV for 5 days followed by tapered oral prednisone or MP 1 g/d IV for 3 days ± oral taper ACUTE ATTACK <ul><li>As of 2011, six treatments have been approved by FDA </li></ul><ul><li>Interferon beta-1a (Avonex, CinnoVex,ReciGen and Rebif) </li></ul><ul><li>Interferon beta-1b (Betaseron ) </li></ul><ul><li>Glatiramer acetate (Copaxone), a non-steroidalimmunomodulator. </li></ul><ul><li>Mitoxantrone, is an immunosuppressant   </li></ul><ul><li>Natalizumab (Tysabri) </li></ul><ul><li>Fingolimod (Gilenya) </li></ul><ul><li>The interferons (s ide effects include flulike symptoms, injection-site reactions, mild liver dysfunction) and glatiramer acetate are delivered by frequent injections, varying from once-per-day for glatiramer acetate to once-per-week (but intra-muscular) for Avonex. Natalizumab and mitoxantrone are given by IV infusion at monthly intervals. </li></ul>DISEASE MODIFYING TREATMENT
  • 11. MANAGEMENT MANAGE MS SYMPTOMS Spasticity Baclofen 5 mg PO 1–3 t.i.d. and increase as needed Diazepam 2–5 mg PO at bedtime Pain NSAIDs Gabapentin effective vs. MS pain syndromes at 300 mg/d PO, may increase to 1,800 mg/d within 1 week, max dose 3,600 mg/d Bladder dysfunction Propantheline 7.5 mg PO q3–4h to start, increase to 15 mg t.i.d. to q.i.d. plus 15–30 mg at bedtime Oxybutynin chloride 5 mg PO t.i.d.–q.i.d. Prophylactic antibiotics for urinary infections Self-catheterizations  for inadequate bladder emptying Constipation: Stool softeners, bulk-producing agents, laxative suppositories Incoordination or tremors: Incoordination or tremors: Depression and emotional lability Antidepressant agents such as SSRIs. Psychotherapy and support Paranoia or mania Haloperidol lithium or atypical antipsychotic Hemifacial and dysesthesias Carbamazepine 100–200 mg PO once or twice a day to start; increase to total daily dosage of 600–1,600 mg t.i.d.–q.i.d. Must monitor serum levels

×